Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-β

作者：Kong, Qing-fei; Sun, Bo; Bai, Sha-sha; Zhai, Dong-xu; Wang, Guang-you; Liu, Yu-mei; Zhang, Shu-juan; Li, Rui; Zhao, Wei; Sun, Yan-yan; Li, Na; Wang, Qj; Peng, Hai-sheng; Jin, Lian-hong; Li, Hu-lun^*

来源：Journal of Neuroimmunology, 2009, 207(1-2): 83-91.

DOI：10.1016/j.jneuroim.2008.12.005

• Bone marrow stromal cells (BMSCs)
• Experimental autoimmune myasthenia gravis (EAMG)
• T helper 17 (Th17)
• Transforming growth factor beta (TGF-beta)

Bone marrow stromal cells (BMSCs) are strong candidates for cell therapy against human autoimmune diseases. Intravenous administration of syngenic BMSCs to EAMG-model rats effectively ameliorated the disease, partially through a TGF-beta-dependent mechanism. The proliferative ability of T or B cells from EAMG rats was inhibited by BMSCs at proper cocultured ratios. And the imbalance of Th1, Th2, Th17 and Treg cell subsets accompanied with the development of EAMG was corrected by the administration of BMSCs. These results provide further insights into the pathogenesis of MG, EAMG, and other immune-mediated diseases, and support a potential role for BMSCs in their treatment.

• 出版日期2009-2-15
• 单位哈尔滨医科大学